These data support the hypothesis that LDN may have potential as a treatment for ME/CFS by characterising the underlying regulatory mechanisms of LDN treatment involving TRPM3 and opioid receptors in NK cells. This evidence concerns the gene TRPM3 and myalgic encephalomeyelitis/chronic fatigue syndrome.